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Nystatin is a pharmacological agent commonly used for the treatment of oral, mucosal
and cutaneous fungal infections. Nystatin has also been extensively applied to study
the cellular function of cholesterol-enriched structures because of its ability to bind and
extract cholesterol from mammalian membranes. In neurons, cholesterol level is tightly
regulated, being essential for synapse and dendrite formation, and axonal guidance.
However, the action of Nystatin on axon regeneration has been poorly evaluated. Here,
we examine the effect of Nystatin on primary cultures of hippocampal neurons, showing
how acute dose (minutes) of Nystatin increases the area of growth cones, and chronic
treatment (days) enhances axon length, axon branching, and axon regeneration post-
axotomy. We describe two alternative signaling pathways responsible for the observed
effects and activated at different concentrations of Nystatin. At elevated concentrations,
Nystatin promotes growth cone expansion through phosphorylation of Akt; whereas, at
low concentrations, Nystatin enhances axon length and regrowth by increasing nitric
oxide levels. Together, our findings indicate new signaling pathways of Nystatin and
propose this compound as a novel regulator of axon regeneration.
Keywords: nystatin, axon growth, nitric oxide synthase, growth cone, axon regrowth post-axotomy
INTRODUCTION
Mammalian adult Central Nervous System (CNS) differs from embryonic CNS and Peripheral
Nervous System (PNS) by their inherent ability to regenerate lesioned tissues. After axotomy,
the first regeneration step requires the formation of a functional growth cone. Unfortunately, the
adult CNS has a reduced capacity to form new growth cones due, to the existence of intrinsic
factors (Ertürk et al., 2007) and the presence of growth-inhibitory molecules (Tan et al., 2005; Li
et al., 2013). After axotomy, organized sequential steps are required to form new and functional
growth cones. The first of which consists of the influx of calcium, which increases exocytosis to
fuse additional membrane to form a sealing patch to repair the ablated axon (Bradke et al., 2012;
Blanquie and Bradke, 2018; Curcio and Bradke, 2018). Following this initial membrane addition,
microtubule and actin cytoskeleton is reorganized, multiple signaling cascades are activated and
Frontiers in Molecular Neuroscience | www.frontiersin.org 1 April 2020 | Volume 13 | Article 56
Roselló-Busquets et al. Nystatin Promotes Axon Extension and Regeneration
the new membrane is transported to the tip of the growing
axon (Bradke et al., 2012; He and Jin, 2016; Curcio and Bradke,
2018). A tight control of the actin cytoskeleton is crucial for the
formation and functionality of the new growth cone. Regulation
of actin requires the initiation of the phosphatidylinositol-
3-kinase (PI3K)/Akt signaling cascade (Henle et al., 2011;
Kakumoto and Nakata, 2013; Berry et al., 2016; Curcio and
Bradke, 2018; Jin et al., 2018). Akt phosphorylation induces the
activation of nitric oxide synthase (NOS), whose function is
associated with actin reorganization and cell survival (Michell
et al., 1999; Van Wagenen and Rehder, 2001; Welshhans and
Rehder, 2005; Cooke et al., 2013; Sild et al., 2016). NOS
produces nitric oxide (NO), a gaseous molecule involved in
neurotransmission, neuronal growth and filopodia formation
(Van Wagenen and Rehder, 2001; Welshhans and Rehder,
2005; Tojima et al., 2009; Forstermann and Sessa, 2012). NO
is also associated with axon regeneration in insect neurons
(Stern and Bicker, 2008) and the snail Helisoma trivolvis
(Cooke et al., 2013). NO cannot be stored in cells, so its
effects depend on the de novo synthesis by NOS activity. From
the three types of NOS, neural NOS (nNOS) is synthesized
in CNS and PNS neurons and its activity is regulated by
intracellular calcium levels. The NO downstream signaling
pathway involves the activation of protein kinase G (PKG)
and actin-associated proteins such as the Enabled/vasodilator-
stimulated phosphoprotein (Ena/VASP), resulting in a strong
reorganization of the actin cytoskeleton (Zhou and Zhu, 2009;
Forstermann and Sessa, 2012; Cossenza et al., 2014).
Nystatin is a drug commonly used as an antifungal
agent because of its ability to destabilize fungal membranes
by binding and extracting ergosterol, causing changes in
cell permeability and, eventually, cell lysis (Bolard, 1986;
Coutinho et al., 2004). Nystatin can also bind to cholesterol
and extract this lipid from the membranes of mammalian
cells. As a consequence, Nystatin has been widely used to
disrupt and study the cellular function of lipid rafts. Lipid
rafts are membrane microdomains enriched in cholesterol
and sphingolipids, that facilitate the compartmentalization
of signaling proteins, working as platforms for spatial and
temporal regulation of the cytoskeleton, membrane anchoring,
and cell adhesion, controlling the motility of growth cones
(Guirland and Zheng, 2007), and the regenerative properties
of lesioned axons (Tassew et al., 2014; Roselló-Busquets
et al., 2019). The extended clinical use of Nystatin, together
with its ability to affect the organization of lipid rafts,
makes it an ideal candidate to explore its function as
a possible therapeutic agent for the treatment of spinal
cord lesions.
Here, we performed an in vitro evaluation of the Nystatin-
induced axonal regenerative properties, analyzing the effect of
various concentrations and incubation times of this compound
in hippocampal neurons. The study of the downstream
signaling proteins responsible for the observed effects of
Nystatin suggested that Nystatin differentially activates Akt
phosphorylation and NO production in a concentration-
dependent manner. We propose Nystatin as a novel neuronal
pharmacological regulator of Akt and nNOS activity that




The following antibodies were used: Mouse Anti-IIIβ-tubulin
(MMS-435P, Covance), Rabbit mAb Anti-P-Akt (Ser473; #4060,
Cell Signaling), Goat Anti-Akt (C-20; sc-1618, Santa Cruz),
Donkey anti-Mouse IgG (H + L) Highly Cross-Adsorbed
Secondary Antibody, Alexa Fluor 488 (A-21202, Thermo
Fisher), Swine Anti-Rabbit Immunoglobulins/HRP (P0217,
Dako), Rabbit Anti-Goat Immunoglobulins/HRP (P0449, Dako).
The following drugs and reagents were used: Poly-D-
Lysine (P7280, Sigma), rat tail collagen Type I, Rat Tail
(354236, Corning), Nystatin dihydrate (N4014, Sigma), DMSO
(D5879, Sigma), Methyl-β-cyclodextrin (C4555, Sigma),
Phalloidin—TRITC (P1951, Sigma), NG-Monomethyl-L-
arginine, monoacetate salt (L-NMMA; ab120137, Abcam),
diamino-fluorescein Diacetate (DAF-FM DA; D-23844,
Molecular Probes), CellTrackerTM RedCMTPX Dye (C34552,
Thermo Fisher), Complete Protease Inhibitor Cocktail
Tablets (11697498001, Roche), MK-2206-2HCl (A10003,
AdooQ Bioscience).
Neuronal Cultures
Hippocampal and forebrain primary cell cultures and explants
were obtained from E16-E17 (embryonic day 16–17) mice
embryos. Pregnant CD1 dams were sacrificed by cervical
dislocation and the fetuses were collected and decapitated.
Brain tissues were maintained during the dissection procedure
constantly submerged in ice-cold 0.3% glucose-phosphate-
buffered saline (PBS) solution. For primary cell cultures,
hippocampi or forebrains were isolated and trypsinized for 6 min
at 37◦C. Trypsin was neutralized with FBS, the tissues were
incubated with DNase I for 10 min at 37◦C, and then they were
mechanically dissociated by gentle trituration. The neurons were
centrifuged at 800 rpm for 5 min, resuspended and plated in
culture glasses pre-coated with 0.5 mg/ml poly-D-lysine. The
composition of the neuronal culture medium was Neurobasal
(w/o L-glutamine, w/ Phenol Red; 21103-049, GIBCO), 1%
penicillin/streptomycin (15140-122, GIBCO), 1% Glutamine
(25030-024, GIBCO) and 2% B27 (17504-044, GIBCO). Explants
were obtained from dissected hippocampi, plated in 15.6 mm
dishes pre-coated culture glasses with 0.5 mg/ml poly-D-lysine
(P7280, Sigma) and 0.03 mg/ml collagen (354236, Corning) with
neuronal culture medium. Explants were cultured for 3 DIV
(3 days in vitro) in the experiments of axon extension, or were
cultured for 7 or 14 DIV in the experiments of axon regeneration.
After 7 or 14 days, axotomy was performed using a hypodermic
needle (302200, BD Microlance) to cut the axons close to the
explant body (Finn et al., 2000). Axotomized explants were
collected using a pipette and moved to a new dish, where they
will be immersed in a collagen matrix. When collagen was
coagulated, culture media was applied (Lumsden and Davies,
1986) and explants were kept in culture for 3 more days with the
corresponding treatments.
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Drug Treatments
For acute treatment experiments on dissociated forebrain and
hippocampal neurons to measure growth cone size, filopodia
density, Akt phosphorylation, and NO formation, cells were
incubated with Nystatin at the following concentrations:
2.5 µM, 10 µM or 25 µM during 30 min. DMSO was used as
vehicle control condition, applied to match the same volume of
Nystatin used.
For chronic treatment experiments on hippocampal explants
and dissociated neurons to measure axonal extension and
regeneration, the samples were incubated with 2.5 µM Nystatin
or DMSO for 3 days. Nystatin was added to the culture medium
immediately after plating dissected neurons (experiments of axon
extension) or after axotomy (experiments of axon regeneration).
Nitric Oxide Experiments
Primary hippocampal neurons were obtained as described
above. After 3 DIV, neurons were pre-incubated with 100 µM
L-NMMA or control medium for 1 h at 37◦C. Immediately after,
the pre-incubation medium was removed and neuronal NO was
labeled by incubating with 5 µM DAF-FM supplemented with
100 µM L-NMMA or control medium for 30 additional minutes
at 37◦C. After three washes with Neurobasal, neurons were
further incubated with 10 µM CellTrackerTM RedCMTPX Dye
in addition to 2.5 µM Nystatin or 0.5 µM MβCD supplemented
with 100 µM L-NMMA or control medium for 30 min at 37◦C.
CellTracker was used as a marker of the surface of the neurons.
Hippocampal explants were cultured with 100 µM L-NMMA
or control medium for 2 h immediately before axotomy was
performed. Explants were then returned to their culture medium
for three additional days in the presence of 2.5 µM Nystatin or
DMSO, supplemented with or without L-NMMA.
Akt Inhibition Experiments
Primary hippocampal neurons were obtained as described above.
After 3 DIV, neurons were pre-incubated with 2 µM MK-2206-
2HCl or control medium for 4 h at 37◦C. Immediately after,
the pre-incubation medium was removed and neurons were
incubated with 2.5, 10, 25 µM Nystatin or control medium
supplemented with or without 2 µMMK-2206-2HCl for 30 min
at 37◦C.
Immunocytochemistry
Hippocampal dissociated cultures were fixed with 4% PFA in PBS
for 10 min at room temperature (RT), permeabilized with 0.1%
PBS-Triton for 10 min. To detect the actin cytoskeleton, neurons
were stained with a solution of 1µg/ml phalloidin-TRITC in PBS
for 30 min, rinsed with PBS and mounted in Mowiol. To detect
P-Akt, Akt or tubulin, neurons were incubated with a blocking
solution, 10% normal horse serum (NHS) in TBS, for 2 h and
with primary antibody diluted in blocking solution for 2 h. Then,
neurons were washed and incubated with secondary antibody
in blocking solution for 1 h rinsed with TPBS and mounted
in Mowiol. To detect cholesterol, neurons were fixed with a
solution of 0.12 mM sucrose in 4% PFA in PBS for 15 min at
RT. Then, neurons were stained with a freshly prepared solution
of 0.05mg/ml filipin in PBS for 90 min, rinsed with PBS, fixed
again with 0.12 mM sucrose in 4% PFA for 20 min and mounted
in Mowiol (Gu et al., 1997; Feng et al., 2003).
Explants were fixed with a solution of 4% PFA in PBS or
30 min at RT. Then, the explants were rinsed with PBS and
permeabilized with a solution of 0.5% Triton X-100 in PBS for
30 min. Explants were then incubated with blocking solution,
NHS 10% in PBS, for 2 h. After blocking, explants were incubated
overnight at 4◦C with the primary antibody diluted in blocking
solution. Explants were then washed three times with PBS and
incubated with the respective secondary antibodies diluted in
blocking solution for 2 h at RT. Finally, explants were washed
three times in PBS and mounted in Mowiol.
Immunoblotting
Forebrain neurons were dissected and cultured in 35 mm
diameter dishes during 3 DIV. On the third day, neurons
were treated with control medium (containing DMSO) or
Nystatin medium (at different concentrations) for 30 min. After
each respective treatment, neurons were placed on ice and
lysed with ice-cold lysis buffer supplemented with a protease
inhibitor cocktail (11697498001, Roche), 10 mM NaF, 1 mM
Na3VO4 and 10 mM Na2H2P2O7. Cell lysates were diluted with
loading buffer and boiled for 5 min. Samples were separated
by electrophoresis using an 8% polyacrylamide gel. Proteins
were transferred to nitrocellulose membranes (10600002, GE
Healthcare Life Sciences) and incubated with different primary
antibody and secondary antibodies. Bands were quantified using
GelPro Analyzer software (version 3.1, Media Cybernetics).
Image Acquisition
Images from explants, growth cones and filopodia were acquired
using an epifluorescence microscope (Eclipse Nikon E1000)
under a 5× and 10× objective (for explants) or a 60×
oil-immersion objective (for growth cones and filopodia). A
confocal microscope (Leica TCS SP5) was used to acquire a
z-stack of images (every 0.5 µm) from DAF-FM and P-Akt
intensity with 63x oil-immersion objective.
Image Analysis and Quantifications
Each experiment contains a mixed culture of neurons isolated
from more than three embryos. All experiments were repeated
three independent times (independent dissections). or the
analysis of growth cone area and filopodia density, actin staining
through phalloidin was used to identify growth cones and
axonal filopodia. Filopodia were manually counted as actin-
enriched protrusions formed in discrete segments along the
axon. Proximal (<50 µm) and distant (>50 µm) axonal regions
were randomly selected for quantifications. The growth cone
compartment was outlined based on a differential staining for
actin in the growth cone concerning the axon compartment. An
intensity threshold mask was created using ImageJ (Schneider
et al., 2012) and the growth cone perimeter was selected using
the wand tool (similar results were obtained by manual selection
of growth cone perimeter). In the DAF-FM experiments, the
intensity was measured (mean gray value × area) inside the
cell body (maximum of Z projections) using ImageJ. The
measurements were normalized to the signal intensity obtained
in control conditions, to avoid basal fluorescence. Between
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20–30 images were acquired for each condition. In P-Akt images,
the intensity was quantified inside growth cones and in the
cell body, and was normalized to the control condition. In the
explant growth and regeneration experiments, the signal from
dapi staining (nuclei) was subtracted from each explant and
considered as the beginning of the axons. In 3 DIV and 7 DIV
explants, the length of eight lines drawn from the beginning of
the axons until their most distal part was measured. In 14 DIV
explants, the 10 longest axons were selected and their length from
the beginning of the axons until their tip was measured. For each
explant, 8 (in 7 DIV) or 10 (in 14 DIV) axon measurements were
obtained and averaged.
Statistical Analysis
All the data shown in the graphs represent the mean ± SEM.
The number of neurons and explants used in each experiment is
specified in the corresponding figure legend. Data was analyzed
using GraphPad software. Normal distribution was evaluated
by applying the D’Agostino and Pearson normality test. Two-
tailed, unpaired Student’s t-test was used to compare two
conditions, and one-way ANOVA with Tukey post hoc test
was used when the experiment had more than two conditions.
Significance is considered when ∗p-value < 0.05, ∗∗p < 0.01,
∗∗∗p < 0.001.
RESULTS
Different Doses of Nystatin Affect Growth
Cone Size
Growth cones play a key role in axon regeneration and
membrane cholesterol levels can modify growth cone
dynamics. Nystatin is a polyene antifungal agent widely
used in experimental research to alter cholesterol levels and
modify the function of lipid rafts. We recently proposed a
reduction of cholesterol levels as a possible strategy to promote
axon regrowth after sciatic nerve lesion (Roselló-Busquets et al.,
2019). However, the potential applicability of Nystatin remains
unexplored. To answer this question, we first analyzed the
effect of different concentrations of Nystatin on the growth
cone area in hippocampal neurons (Figure 1). We cultured
mice hippocampal neurons for 3 days in vitro (3 DIV) and
treated them acutely with different widely used concentrations of
Nystatin, from high doses that can removemembrane cholesterol
(25 µM) to low doses that do not affect cholesterol levels
(2.5µM; Johnson et al., 1998; Koide et al., 2009; Kim et al., 2013).
All three concentrations tested, 2.5 µM (Figures 1A,D), 10 µM
(Figures 1B,E) and 25 µM (Figures 1C,F) increased growth
cone area (Figure 1G).
Different Doses of Nystatin Affect
Differentially Akt Phosphorylation
The results from Figure 1 suggest a cholesterol-independent
effect of Nystatin in controlling growth cone dynamics. To
find out the mechanism through which Nystatin is increasing
growth cone size, we studied whether Akt phosphorylation
is affected under our three Nystatin concentrations tested.
Western Blot analysis of P-Akt/Akt levels from primary cultured
forebrain neurons treated with 2.5 µM, 10 µM and 25 µM
of Nystatin (Figure 2A) revealed no significant differences,
but only a tendency in increasing Akt phosphorylation
under the highest dose tested (Figure 2B). However, the
evaluation of specific P-Akt levels in growth cones (Figure 2C)
and cell bodies by immunocytochemistry assay showed that
only the highest doses of Nystatin (10 µM and 25 µM)
significantly increase Akt phosphorylation locally inside growth
cones (Figure 2D).
High Doses of Nystatin Increase Growth
Cone Area Through Akt Phosphorylation
To analyze whether Nystatin Akt phosphorylation is required for
the observed effects of Nystatin on growth cones, we used the Akt
inhibitor MK-2206. Whereas lowest concentration of Nystatin
(2.5 µM) increases growth cone area independently of Akt
inhibition (Figures 3A,D), the effect induced by highest doses
(10 µM and 25 µM) depends on Akt activity (Figures 3B,C,E,F).
These results are consistent with the phosphorylation of Akt
in growth cones. Immunocytochemistry analysis of P-Akt/Akt
levels within growth cones revealed that those concentrations of
Nystatin that increased Akt phosphorylation also affected growth
cone dynamics in an Akt-dependent manner (Figures 3G–I).
Nystatin Increases Axon Growth in
Hippocampal Explants
We then wanted to evaluate whether chronic treatments of
Nystatin promote axonal growth in hippocampal neurons. To
avoid possible toxicity effects of longer exposure to Nystatin,
we used the lowest concentration tested (2.5 µM) which was
sufficient to promote a significant increase in growth cone
size (Figure 4). Hippocampal explants were cultured inside
a collagen matrix with control media (Figure 4A) or with
2.5 µM Nystatin-containing media (Figure 4B) for 3 days. The
length of explant-protruding axons was analyzed, revealing that
chronic exposure to a low concentration of Nystatin promotes
axon growth (Figure 4C). We then used primary cell cultures of
hippocampal neurons (Figures 4D,E) to study the chronic effect
of 2.5µMNystatin on axonal growth and branching. After 3 days
of incubation with Nystatin, we found increases on both axon
length and axonal branching (Figure 4F).
Nystatin Increases the Growth Cone Area
and Filopodia Density Through NO
Production
Our results suggest a cholesterol and Akt phosphorylation
independent effect on growth cone dynamics by low
concentrations of Nystatin in acute (min) and chronic (days)
treatments. NO is a gaseous secondmessenger that participates in
actin cytoskeleton remodeling, filopodia formation (Welshhans
and Rehder, 2005) and growth cone guidance (Tojima et al.,
2009). To evaluate whether the observed effects of low
concentrations of Nystatin on growth cones depend on NO
production, we incubated hippocampal neurons with a NOS
inhibitor (L-NMMA) and detected the formation of NO using
Diamino-fluorescein Diacetate (DAF-FM DA), a cell-permeable
reagent used to quantify low concentrations of NO in solution.
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FIGURE 1 | Acute incubation with different concentrations of Nystatin increases the growth cone size of hippocampal neurons. Representative images of growth
cones from hippocampal neurons cultured during 3 DIV and incubated with control medium (DMSO; A–C) or Nystatin at 2.5 µM (D), 10 µM (E) and 25 µM (F) for
30 min. Growth cone area quantification for each treatment (G). Neuronal actin was stained incubating cells with phalloidin-TRITC (1 µg/ml) for 30 min. Data shows
mean ± SEM. n = 80–120 neurons in each condition. Two-tailed, unpaired Student’s t-test was performed. ∗∗p < 0.01, ∗∗∗p < 0.001. Scale bar 5 µm.
DAF-FM DA remains non-fluorescent until it is hydrolyzed
to DAF-FM by intracellular esterases, allowing its reaction
with NO to form a fluorescent benzotriazole. DAF fluorescent
intensity was quantified, revealing increased levels of NO upon
low-dose Nystatin treatment (Figures 5A–C). Importantly,
the treatment of neurons with the highest concentrations of
Nystatin (10 µM and 25 µM) did not affect NO production
(Figures 5D,E). The effect of Nystatin in the growth cone area
(Figure 6A) and filopodia density (Figure 6B) was prevented
by NOS inhibition (Figures 6C,D), suggesting NO production
as an alternative mechanism used by Nystatin to modulate axon
dynamics at low concentrations. Consistent with the lack of
action on NO production, the effect of highest doses of Nystatin
(10 µM and 25 µM) on growth cone area and filopodia density
is independent of NOS inhibition (Figures 6E–H). Methyl-beta-
cyclodextrin (MβCD) is a compound that, similar to Nystatin,
extracts cholesterol from cell membranes, increasing growth
cone area and filopodia number (Roselló-Busquets et al., 2019).
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FIGURE 2 | Dose-specific Nystatin effect to Akt phosphorylation. Western blots from E16 cortex primary cell cultures, cultured during 3 DIV and incubated with
control medium (DMSO) or Nystatin 2.5 µM, 10 µM or 25 µM for 30 min. P-Akt and Akt were detected (A). The ratio of P-Akt/Akt was quantified with Gelpro
software. n = 3 neuronal extracts in each condition. Two-tailed, unpaired Student’s t-test was performed (B). Representative images of hippocampal growth cones
treated with Nystatin at the doses described above, stained with phalloidin and labeled against P-Akt (C). Quantification of the relative P-Akt intensity in the growth
cones and neuronal cell bodies (D). Data shows mean ± SEM. n = 30–50 neurons in each condition. Two-tailed, unpaired Student’s t-test was performed.
∗p < 0.05, ∗∗∗p < 0.001. Scale bar 5 µm.
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FIGURE 3 | Effect on growth cone size by high concentrations of Nystatin requires Akt phosphorylation. Representative images of growth cones from hippocampal
neurons cultured during 3 DIV and incubated with Nystatin at 2.5 µM (A), 10 µM (B) and 25 µM (C) for 30 min in the presence or not of Akt inhibitor MK-2206.
Growth cone area quantification for each treatment (D–F). Neuronal actin was stained incubating cells with phalloidin-TRITC (1 µg/ml) for 30 min.
Immunocytochemistry quantification of the ratio of P-Akt/Akt in growth cones for each treatment (G–I). Data shows mean ± SEM. n = 20–30 neurons for Akt
intensity and 150–200 neurons for growth cone area in each condition. One-way ANOVA, Tukey’s multiple comparison test; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.
Scale bar 5 µm.
NOmeasurement using DAF-FM showed that MβCD treatment
did not affect NO production (Supplementary Figure S1).
These results suggest that the growth cone area and filopodia
number can be modulated by decreasing cholesterol levels
or by regulating NO production using low concentrations
of Nystatin.
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FIGURE 4 | Chronic treatment of Nystatin increases axon length and
branching in hippocampal neurons. Representative images of hippocampal
explants cultured inside a collagen matrix (A,B) or dissociated neurons (D,E),
cultured in the presence of DMSO control media (A,D) or 2.5 µM Nystatin
(B,E) for 3 DIV. Axon length quantification from explants (C) or dissociated
neurons (F, upper graph). Quantification of the density of branching points in
the axon (F, lower graph). Neuronal class III β-tubulin was immunoassayed to
identify axons and measure their length. Data shows mean ± SEM.
n = 15–20 explants, 200 neurons in each condition. Two-tailed, unpaired
Student’s t-test was performed ∗∗∗p < 0.001. Scale bar 250 µm (A,B),
50 µm (D,E).
Nystatin Increases Axon Regeneration in
Immature and Differentiated Hippocampal
Explants Through NO Production
Previous results showed that Nystatin increases axon
regeneration post-axotomy in primary cell cultures of
hippocampal neurons (Roselló-Busquets et al., 2019). The
ability of axons to regenerate is lost in adult CNS neurons
(He and Jin, 2016; Curcio and Bradke, 2018; Fawcett, 2019).
Primary CNS neuronal cultures lose their regenerative capacities
during their in vitro differentiation (del Rio and Soriano, 2010).
To study whether low concentrations of Nystatin promote
axon regeneration post-axotomy and whether this effect is
maintained in differentiated neurons, we performed axotomy
experiments with hippocampal explants cultured during 7 and
14 DIV (Figures 7A,B). Then, axon explants were mechanically
ablated and further regrowth for 3 DIV in the presence of
2.5 µM Nystatin supplemented with the NOS inhibitor
L-NMMA (Figures 7C–J). Quantification of axon length
revealed that Nystatin promotes regrowth of axons after axotomy
regardless of the differentiation state of the neuronal cultures,
and in a process that requires NO production (Figures 7C–K).
DISCUSSION
This study examines the mechanisms through which Nystatin, a
drug used normally to treat fungal infections, enhances axonal
growth and regeneration using differential dose-dependent
mechanism. We demonstrate that only high concentrations
of Nystatin increase the size of growth cones through Akt
phosphorylation, whereas low concentrations exert the same
effect by promoting NO production. The formation of NO is
necessary for the chronic effect of Nystatin on modulating axon
dynamics and promoting regeneration post-axotomy.
Nystatin can activate Akt phosphorylation in macrophages
(Kim et al., 2013), but to date, the effect has completely been
unexplored in neurons. The combination of Western Blot, Akt
inhibitor, and immunocytochemistry analysis revealed a local
growth cone increase of Akt phosphorylation. This effect is
specifically localized in growth cones, explaining why it was
not detected by Western Blotting. Activation of the PI3K/Akt
pathway in growth cones produces an increase of the exocytosis
(Laurino et al., 2005), a process necessary for membrane
expansion and axon growth (Pfenninger, 2009; Cotrufo et al.,
2011). Although low concentrations of Nystatin also increased
the growth cone area, they did not enhance Akt phosphorylation.
High concentrations of Nystatin require Akt phosphorylation
to induce their effect on growth cone dynamics. It has been
previously described that low doses of Nystatin increases NO
levels in macrophage-like cell lines (Koide et al., 2009), but
this effect had not been previously described in neurons. Our
results are in agreement and suggest an alternative mechanism
where Nystatin only at low concentrations controls growth
cone dynamics by modifying NO levels. These results suggest
that depending on its concentration, Nystatin could be acting
through different pathways. High doses of Nystatin also remove
membrane cholesterol from cell membranes; however, alteration
of cholesterol levels using an elevated concentration of Nystatin
does not affect NO production.
There is a discrepancy in the literature about the benefits of
NO increments on neurites and growth cones. NO is necessary
for neurite growth, axon guidance and filopodia length (Van
Wagenen and Rehder, 2001; Welshhans and Rehder, 2005;
Cooke et al., 2013; Sild et al., 2016). However, NO has also been
associated with a growth cone collapse (Cossenza et al., 2014;
Frontiers in Molecular Neuroscience | www.frontiersin.org 8 April 2020 | Volume 13 | Article 56
Roselló-Busquets et al. Nystatin Promotes Axon Extension and Regeneration
FIGURE 5 | Nystatin increases nitric oxide production in hippocampal neurons. Representative images of hippocampal neurons stained with CellTrackerTM Dye
(A) and DAF-FM (B) to detect nitric oxide production under the presence of DMSO control conditions (± the NOS inhibitor L-NMMA) or 2.5 µM Nystatin (± the NOS
inhibitor L-NMMA) incubated during 30 min. Images in (B) are shown in a pseudo-color scale where magenta color indicates high levels of NO and blue color
indicates low levels of NO. DAF-FM intensity was quantified in each condition and presented relative to the DMSO control condition (C). Similarly, DAF-FM intensity
was also quantified for neurons treated with 10 µM Nystatin (D) or 25 µM Nystatin (E) and presented relative to DMSO control condition. Data shows mean ± SEM.
For each condition, n = 20–30 neurons were used for DAF intensity, n = 150–200 growth cones (one per neuron) for growth cone area, and n = 40–60 axons for
filopodia density. One-way ANOVA, Tukey’s multiple comparison test; ∗∗p < 0.01, ∗∗∗p < 0.001. Scale bar 5 µm.
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FIGURE 6 | Acute treatment of Nystatin increases growth cone and filopodia density trough nitric oxide production. Representative images of growth cones (A) and
filopodia (B) treated during 30 min with DMSO (± L-NMMA) or 2.5 µM Nystatin (± L-NMMA). Quantification of growth cone area (C) and filopodia density (D) for
each treatment under DMSO or 2.5 µM Nystatin. Similarly, growth cone area (E,G) and filopodia density (F,H) were also quantified for neurons treated with 10 µM
Nystatin (E,F) or 25 µM Nystatin (G,H). Neuronal actin was used to identify growth cone morphology and axon filopodia. Actin was stained by incubating cells with
phalloidin-TRITC (1 µg/ml) for 30 min. Data shows mean ± SEM. n = 20–30 neurons in each condition. One-way ANOVA’s multiple comparison test; ∗p < 0.05,
∗∗∗p < 0.001. Scale bar 5 µm.
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FIGURE 7 | Chronic treatment of Nystatin increases axon regeneration through nitric oxide production. Scheme of axotomy procedure (A). Representative
bright-field images of explants before axotomy (Bi) and immediately after axotomy (Bii). Representative immunofluorescence image of an explant 3 days after
axotomy (Biii). Scale bar 200 µm. Representative images of hippocampal explants axotomized after 7 DIV or 14 DIV and regrowth for three additional days inside a
collagen matrix in control medium (C–F) or 2.5 µM Nystatin (G–J), and without the NOS inhibitor L-NMMA (C,E,G,I) or with the NOS inhibitor L-NMMA (D,F,H,J).
Neuronal class III β-tubulin was immunoassayed to identify axons and measure their length. Quantification of explant axon length (K). Data shows mean ± SEM.
n = 25–30 explants in each condition. One-way ANOVA, Tukey’s multiple comparison test; ∗p < 0.05, ∗∗∗p < 0.001. Scale bar 250 µm.
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Redondo et al., 2015). This discrepancy could be explained by
the fact that NO effects depend on its concentration and the
multiple possible interactions with other molecules. While low
to moderate increment of NO levels is beneficial for cell survival,
a high increment of NO concentration is associated with cell
death (Cossenza et al., 2014). By using NOS inhibitors we find
that the increment of NO-induced by only by low concentrations
of Nystatin is required to promote axon regeneration
after axotomy.
Disruption of cell membrane permeability has also been
associated with the production of reactive oxygen species (ROS).
It has been described that an increment in ROS levels is
necessary to initiate axon regeneration after sciatic nerve and
spinal cord injury (Hervera et al., 2018), and to regulate F-actin
dynamics in the growth cones and neurite outgrowth through
Rac1 (Munnamalai and Suter, 2009). NO degradation results
in the formation of ROS. Mutations in Cu/Zn superoxide
dismutase (SOD1), an enzyme that converts superoxide radicals
to molecular oxygen and hydrogen peroxide, are associated with
increments of growth cone area, filopodia density, axonal growth
and branching in adult motor neurons due to the accumulation
of ROS (Osking et al., 2019). The formation of ROS as secondary
sub-products of NO formation could be involved in the observed
phenotype after Nystatin treatments.
In conclusion, here we demonstrate that Nystatin could
activate two different pathways in neurons, PI3K/Akt and
nNOS/NO, and that nNOS activity is necessary for axonal
regeneration when Nystatin is applied chronically at 2.5 µM.
With this study, we propose that Nystatin, a drug currently used
as an antifungal agent and to extract cholesterol from the cell
membranes, might have an alternative effect improving axon
growth and regeneration. Our findings suggest Nystatin as an
interesting candidate molecule to be tested in neuronal re-growth
and repair.
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FIGURE S1 | Cholesterol disruption with MβCD does not affect nitric oxide
production. Representative images of hippocampal neurons stained with
CellTrackerTM Dye (A) and DAF-FM (B) to detect nitric oxide production under
control conditions (± the NOS inhibitor L-NMMA) or 0.5 µM MβCD (± the NOS
inhibitor L-NMMA). Images in (B) are shown in a pseudo-color scale where
magenta color indicates high levels of NO and blue color indicates low levels of
NO. DAF-FM intensity was quantified in each condition and presented relative to
the DMSO control condition (C). Data shows mean ± SEM. n = 20–30 neurons in
each condition. One-way ANOVA, Tukey’s multiple comparison test.
Scale bar 5 µm.
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